EBGLYSS Trademark

Trademark Overview


On Tuesday, July 13, 2021, a trademark application was filed for EBGLYSS with the United States Patent and Trademark Office. The USPTO has given the EBGLYSS trademark a serial number of 90824942. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Thursday, May 16, 2024. This trademark is owned by Eli Lilly and Company. The EBGLYSS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and diagnosis of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders; pharmaceutical preparations for the treatment, prevention and diagnosis of cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders; pharmaceutical preparations for the treatment, prevention and diagnosis of fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders; p...
ebglyss

General Information


Serial Number90824942
Word MarkEBGLYSS
Filing DateTuesday, July 13, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateThursday, May 16, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 26, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and diagnosis of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders; pharmaceutical preparations for the treatment, prevention and diagnosis of cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders; pharmaceutical preparations for the treatment, prevention and diagnosis of fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders; pharmaceutical preparations for the treatment, prevention and diagnosis of neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 17, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, March 21, 2022ASSIGNED TO EXAMINER
Tuesday, March 22, 2022EXAMINERS AMENDMENT -WRITTEN
Friday, July 16, 2021NEW APPLICATION ENTERED
Friday, September 17, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 22, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 22, 2022EXAMINER'S AMENDMENT ENTERED
Tuesday, March 22, 2022EXAMINERS AMENDMENT E-MAILED
Tuesday, March 22, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, April 26, 2022PUBLISHED FOR OPPOSITION
Wednesday, April 6, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 26, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, November 23, 2022SOU EXTENSION 1 FILED
Tuesday, June 21, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, November 23, 2022SOU TEAS EXTENSION RECEIVED
Monday, December 5, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, December 5, 2022SOU EXTENSION 1 GRANTED
Tuesday, December 6, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 15, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, May 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 16, 2024SOU TEAS EXTENSION RECEIVED
Monday, May 15, 2023SOU EXTENSION 2 FILED
Monday, May 15, 2023SOU EXTENSION 2 GRANTED
Monday, November 13, 2023SOU TEAS EXTENSION RECEIVED
Monday, November 13, 2023SOU EXTENSION 3 FILED
Monday, November 13, 2023SOU EXTENSION 3 GRANTED
Thursday, May 16, 2024SOU EXTENSION 4 GRANTED
Thursday, May 16, 2024SOU EXTENSION 4 FILED
Friday, May 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 13, 2024TEAS STATEMENT OF USE RECEIVED